10-Q quarterly report · filed Nov 5, 2026

AGIOS PHARMACEUTICALS, INC. (AGIO) Q3 2026 10-Q Quarterly Report

Short answer

AGIOS PHARMACEUTICALS, INC. (AGIO) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $55M (up 330.0% year over year) with net income of −$65M.

Q3 2026 key financials · XBRL

Revenue
$55M
+330.0% YoY · +23.8% QoQ
Net income
−$65M
+37.1% YoY · +35.4% QoQ
Operating margin
-139.3%
EPS (diluted)
−$1.08
+39.3% YoY · +36.1% QoQ

Source: XBRL data from the AGIOS PHARMACEUTICALS, INC. (AGIO) Q3 2026 10-Q on SEC EDGAR. USD.

AGIOS PHARMACEUTICALS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $55.4M, up $42.5M YoY from $12.9M, driven by AQVESME® sales
  • Net loss $65.0M vs $103.4M YoY, with operating expenses $132.5M vs $129.7M
  • Best-performing line: U.S. product revenue $48.7M vs $12.3M, driven principally by AQVESME®
  • Cash, equivalents and marketable securities $907.0M; operating cash outflow $235.5M for nine months
  • PDUFA date for mitapivat in SCD extended to February 1, 2027; potential headwinds include increased commercialization costs and further capital needs

Risk Factors

  • New legal risk: Annora’s April 17, 2026 Paragraph IV challenge to PYRUKYND® patents triggered infringement litigation filed May 26, 2026
  • Regulatory risk: FDA requested mitapivat SCD REMS information, extending the PDUFA goal date to February 1, 2027
  • Operational risk: AQVESME® commercialization depends on REMS compliance, with FDA enforcement possible for failures by Agios or its service provider
  • Competitive risk: Generic PYRUKYND® entry could follow patent litigation, although FDA approval is stayed until at least August 17, 2029
  • Financial risk: Nine-month 2026 net loss reached $264.9 million, with accumulated deficit of $826.6 million as of September 30, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other AGIOS PHARMACEUTICALS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.